Clearside jumps as eye disease drug succeeds in mid-stage trial

Clearside Biomedical,

09/10/2024 12:04

** Shares of drug developer Clearside Biomedical  CLSD.O 
rise ~38.5% to $2.05 premarket
    ** Company says its drug CLS-AX showed stable vision in
patients with wet age-related macular degeneration for up to 6
months compared to Regeneron Pharmaceuticals'  REGN.O 
aflibercept, during a mid-stage trial
    ** Wet AMD is a disorder where abnormal blood vessels grow
in the back of the eye, causing vision loss
    ** Up to last close, Clearside stock up 26.5% YTD
    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))